ArticleDigestive diseases and sciences2026
Compartment-Specific Immunohistochemical Alterations Along the Colorectal Adenoma-Carcinoma Continuum.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) progresses through the adenoma-carcinoma sequence, yet the contribution of tumor microenvironment (TME) alterations remains unclear. This study investigated whether the distribution of CD204-positive macrophages, COL11A1-positive stromal cells, and MFAP5 expression patterns differed across colorectal lesion categories and evaluated the diagnostic relevance of integrated TME biomarkers. Expression patterns of CD204, COL11A1, MFAP5, and p53 were analyzed across stages of CRC polyp progression.
methodsA total of 154 CRC lesions-low-grade dysplasia (LGD), high-grade dysplasia (HGD), adenomas with intramucosal carcinoma (IMC), and malignant polyps (MP)-were retrospectively examined. Immunohistochemistry assessed CD204-positive tumor-associated macrophages within lesions (iCD204) and in the perilesional TME (pCD204), COL11A1 (cancer-associated fibroblasts), MFAP5 (ECM integrity), and p53 (epithelial genomic instability). Statistical, trend, correlation, and ROC analyses were performed.
resultsSignificant differences in TME-related marker distributions were observed across the LGD-HGD-IMC-MP spectrum. While iCD204 showed minimal variation, pCD204 density increased progressively with dysplasia grade (p < 0.001) and demonstrated superior discriminatory performance in ROC analyses, particularly for LGD vs. HGD and IMC vs. MP (p < 0.05). MFAP5 expression inversely correlated with dysplasia (p < 0.001), was preserved in pseudoinvasion, and markedly reduced in true invasion. COL11A1 showed variable expression without a consistent stage-related trend; however, moderate positive correlations between COL11A1 and both intralesional and perilesional CD204-positive macrophages were observed only in the HGD subgroup. p53 positivity increased significantly with lesion grade (p < 0.001) and positively correlated with pCD204.
conclusionTME-specific immunohistochemical marker distributions differed across colorectal lesion categories. Perilesional CD204-positive macrophage counts demonstrated discriminatory ability in several lesion-group comparisons, whereas MFAP5 expression showed distinct staining patterns between pseudoinvasive and invasive lesions. COL11A1 expression did not demonstrate a consistent category-associated trend but showed moderate correlations with CD204-positive macrophage counts in the HGD subgroup. These findings should be considered exploratory and require validation in larger independent cohorts.
Indexed as
Identifiers
42606680What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.